Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand

Frontiers in Allergy

Allergy

Françoise Codreanu-Morel¹  Christiane Hilger²  Annette Kuehn²  Theresa-Maria Boehm³  Isabela Assugeni³  Naphisabet Wanniang³  Amandine Divaret-Chauveau⁴ 

[1] Department of Allergology and Immunology, Centre Hospitalier de Luxembourg-Kanner Klinik, Luxembourg, Luxembourg;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg;Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg;Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg;Pediatric Allergy Department, Children’s Hospital, University of Nancy, Vandœuvre-lès-Nancy, France;EA3450 DevAH, Faculty of Medecine, University of Lorraine, Vandoeuvre-lès-Nancy, France;

关键词: oral immunotherapy;    peanut allergy;    immune response;    immunophenotyping;    immunotherapy;    food allergy;   

DOI  :  10.3389/falgy.2023.1270344

 received in 2023-07-31, accepted in 2023-09-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

Peanut allergy is a growing health concern that can cause mild to severe anaphylaxis as well as reduced quality of life in patients and their families. Oral immunotherapy is an important therapeutic intervention that aims to reshape the immune system toward a higher threshold dose reactivity and sustained unresponsiveness in some patients. From an immunological point of view, young patients, especially those under 3 years old, seem to have the best chance for therapy success. To date, surrogate markers for therapy duration and response are evasive. We provide a comprehensive overview of the current literature state regarding immune signatures evolving over the course of oral immunotherapy as well as baseline immune conditions prior to the initiation of treatment. Although research comparing clinical and immune traits in the first years of life vs. later stages across different age groups is limited, promising insights are available on immunological endotypes among peanut-allergic patients. The available data call for continued research to fill in gaps in knowledge, possibly in an integrated manner, to design novel precision health approaches for advanced therapeutic interventions in peanut allergy.

【 授权许可】

Unknown   
© 2023 Wanniang, Boehm, Codreanu-Morel, Divaret-Chauveau, Assugeni, Hilger and Kuehn.